Results 141 to 150 of about 492,046 (298)

Nonhuman Primate Models for HIV Cure Research [PDF]

, 2012
Cristian Apetrei, Ivona Pandrea, John W. Mellors, Richard A. Koup   +3 more
core   +3 more sources

Single‐Cell RNA Sequencing Informs Precision Targeting of Monogenic Lupus Associated With IKZF1 Haploinsufficiency

Arthritis &Rheumatology, EarlyView.
Objective This study aimed to investigate the mechanisms of immune dysregulation in a pediatric patient with monogenic lupus driven by IKZF1 haploinsufficiency. Methods Peripheral immune cells from a patient with IKZF1 haploinsufficiency, patients with lupus with no currently known genetic mutations, and healthy controls were analyzed using single‐cell
Qi Zheng, Yejun Tan, Zhaoling Wang, Yanjie Qian, Qian Ma, Danping Shen, Meiping Lu   +6 more
wiley   +1 more source

Immunoglobulin replacement therapy in primary immunodeficiency disorders: Pragmatic review and evidence mapping. [PDF]

J Allergy Clin Immunol Glob
Carr E, McCool R, Ferrante di Ruffano L, Arber M, Reddish K, Burns J, Holcomb-Selbert R, Abdalgani M, Orange JS.   +8 more
europepmc   +1 more source

Differences in SARS‐CoV‐2 antigen persistence in individuals with systemic autoimmune rheumatic diseases compared to the general population: A RECOVER‐Adult Cohort Study

Arthritis &Rheumatology, Accepted Article.
Background Individuals with systemic autoimmune rheumatic diseases (SARDs) are at risk for worse acute and post‐acute COVID‐19 outcomes, though whether individuals with SARDs have longer persistence of viral antigens after COVID‐19 has not been studied.
Naomi J. Patel, Zoe Swank, Jiaqi Wang, Xiaosong Wang, Lauren A. O'Keeffe, Madison Negron, Liya S. Getachew, Louise L. Hansen, Grace Qian, Alene A. Saavedra, Kevin T. Mueller, Natalie A. Davis, Kathleen M.M. Vanni, Sandria Savage, Julie S. Lam, Zachary S. Wallace, David R. Walt, Jeffrey A. Sparks, RECOVER‐Adult   +18 more
wiley   +1 more source

Comparison of clinical characteristics in primary immunodeficiency patients based on the presence of autoimmunity or autoinflammation. [PDF]

Allergy Asthma Proc
Kolak S, Çölkesen F, Gerek ME, Sağun F, Harman E, Savaş ŞA, Arslan Ş.   +6 more
europepmc   +1 more source

Pharmacokinetic modelling of intravenous immunoglobulin in children with primary immunodeficiencies and secondary antibody deficiencies

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aims Children with primary immunodeficiency (PID) and secondary antibody deficiency (SAD) often require immunoglobulin replacement therapy due to low plasma immunoglobulin G (IgG) levels and recurrent infections. Existing pharmacokinetic models for immunoglobulin in PID patients predominantly focus on adults, with limited attention to ...
Iek Leng Cheng, Zhong Hui Huang, Austen Worth, Claire Booth, Joseph F. Standing   +4 more
wiley   +1 more source

Pharmacokinetics of hyaluronidase-facilitated subcutaneous immunoglobulin 10% in pediatric patients with primary immunodeficiency disease. [PDF]

Immunother Adv
Li Z, Teng Y, Russo-Schwarzbaum S, McCoy B.   +3 more
europepmc   +1 more source

Active surveillance of drug safety in healthcare data: Sequential monitoring of bacterial and serious urinary tract infection risk in sodium‐glucose cotransporter 2 inhibitor users

British Journal of Clinical Pharmacology, EarlyView.
Abstract Introduction Active surveillance of adverse events using healthcare data is emerging as complementary to the monitoring of spontaneous reports and stand‐alone pharmacoepidemiologic studies. The risk of urinary tract infections (UTIs) was listed as a special warning for sodium‐glucose cotransporter‐2 inhibitors (SGLT2is) when marketed in Europe
Haoxin Le, Dilsad Simay Peker, Lukas Frederic Westphal, Nikolai Brun, Christine Erikstrup Hallgreen, Morten Andersen   +5 more
wiley   +1 more source

Genetic and epidemiological patterns of primary immunodeficiency diseases in Eastern Iranian patients. [PDF]

Sci Rep
Salehi M, Ahanchian H, Karimiani EG, Aelami MH, Moazzen N, Neshati Z, Pasdar A.   +6 more
europepmc   +1 more source

Repeated intradermal lipopolysaccharide challenge responses in healthy volunteers: Implications for clinical pharmacology studies

British Journal of Clinical Pharmacology, EarlyView.
Aim Intradermal application of lipopolysaccharide (LPS), a Toll‐like receptor 4 agonist, induces a local inflammatory response and is used as a human challenge model to evaluate the pharmacodynamics of investigational medicinal products. While currently applied in a single, parallel‐group setting, alternative within‐subject designs involving repeated ...
Alexandra A. J. Sillé, Juliette A. van den Noort, Iva Lelios, Diana R. Pereira, Marzia A. Scelsi, Erica S. Klaassen, Philipp Schoenenberger, Naomi B. Klarenbeek, Pierre‐Eric Juif, Pascal Espie, Manon A. A. Jansen, Matthijs Moerland, Richard W. D. Welford   +12 more
wiley   +1 more source